Serum Levels of Adipocyte Fatty Acid–Binding Protein are Independently Associated with Left Ventricular Mass and Myocardial Performance Index in Obstructive Sleep Apnea Syndrome

Balcı, Mustafa; Arslan, Uğur; Fırat, Hikmet; Kocaoğlu, &Idot;brahim; Vural, Mutlu; Balcı, Kevser Gülcihan; Maden, Orhan; Gürbüz, Oğuz Alp; Ardıç, Sadık; Yeter, Ekrem

doi:10.2310/jim.0b013e31826868f2

Cited by 25 publications

(21 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison, we observed only a modest attenuation of longitudinal systolic function in subjects with intermediate and high FABP4 concentrations and preserved ejection fraction. Our data add to other recent work in humans, which failed to show an association between FABP4 and present30 or future16 systolic dysfunction in subjects without prevalent cardiac disease. In contrast, an independent correlation between elevated serum FABP4 and deterioration of LV function was recently reported in non-obese patients hospitalised for acutely decompensated heart failure 36.…”

Section: Discussionsupporting

confidence: 83%

“…In our study, women with increased FABP4 serum concentrations had higher LV mass compared with women in the low FABP4 tertile. In a recent study in patients with obstructive sleep apnoea syndrome, serum FABP4 levels correlated modestly with LV hypertrophy 30. Similarly, we found a modest positive correlation, which remained significant after adjustment for anthropometric measures and metabolic risk factors.…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese women

Engeli

Utz

Haufe

et al. 2013

Heart

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionsupporting

confidence: 77%

Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese women

Engeli

Utz

Haufe

et al. 2013

Heart

View full text Add to dashboard Cite

show abstract

“…133 In other small studies, plasma FABP4 can predict the development of type 2 diabetes mellitus independent of the presence of obesity, 134 is an independent biomarker of insulin resistance, 135 predicts early death in patients with stroke, 136 and is elevated in patients with severe obstructive sleep apnoea syndrome. 137 Independently of obesity, circulating FABP4 is also higher in patients with breast cancer than in healthy individuals, 138 is associated with vascular inflammation, 139 and is predictive of the development of insulin resistance in recipients of liver transplants. 140 Consequently, a large and growing body of evidence supports a strong link between circulating levels of FABP4, obesity and metabolic disease (Figure 3, Supplementary file 1).…”

Section: Circulating Fabp4 and Metabolic Pathologymentioning

confidence: 99%

Metabolic functions of FABPs—mechanisms and therapeutic implications

Hotamışlıgil¹,

2015

View full text Add to dashboard Cite

Intracellular and extracellular interactions with proteins enables the functional and mechanistic diversity of lipids. Fatty acid-binding proteins (FABPs) were originally described as intracellular proteins that can affect lipid fluxes, metabolism and signalling within cells. As the functions of this protein family have been further elucidated, it has become evident that they are critical mediators of metabolism and inflammatory processes, both locally and systemically, and therefore are potential therapeutic targets for immunometabolic diseases. In particular, genetic deficiency and small molecule-mediated inhibition of FABP4 (also known as aP2) and FABP5 can potently improve glucose homeostasis and reduce atherosclerosis in mouse models. Further research has shown that in addition to their intracellular roles, some FABPs are found outside the cells, and FABP4 undergoes regulated, vesicular secretion. The circulating form of FABP4 has crucial hormonal functions in systemic metabolism. In this Review we discuss the roles and regulation of both intracellular and extracellular FABP actions, highlighting new insights that might direct drug discovery efforts and opportunities for management of chronic metabolic diseases.

show abstract

“…Clinical findings suggest that A-FABP is implicated in cardiac dysfunction because raised serum A-FABP levels are associated with left ventricular diastolic dysfunction [12] and cardiac contractile dysfunction [13] in obese patients, or elevated left ventricular mass and reduced myocardial performance index in patients with obstructive sleep apnoea [14]. The circulating level of A-FABP independently correlates with the severity of heart failure in Chinese individuals [15] and is associated with increased risk of heart failure in older patients in the U.S.A. [16].…”

Section: Introductionmentioning

confidence: 99%

Deficiency of adipocyte fatty-acid-binding protein alleviates myocardial ischaemia/reperfusion injury and diabetes-induced cardiac dysfunction

Zhou

Bao

et al. 2015

Clinical Science

View full text Add to dashboard Cite

Clinical evidence shows that circulating levels of adipocyte fatty-acid-binding protein (A-FABP) are elevated in patients with diabetes and closely associated with ischaemic heart disease. Patients with diabetes are more susceptible to myocardial ischaemia/reperfusion (MI/R) injury. The experiments in the present study investigated the role of A-FABP in MI/R injury with or without diabetes. Non-diabetic and diabetic (streptozotocin-induced) A-FABP knockout and wild-type mice were subjected to MI/R or sham intervention. After MI/R, A-FABP knockout mice exhibited reductions in myocardial infarct size, apoptotic index, oxidative and nitrative stress, and inflammation. These reductions were accompanied by an improved left ventricular function compared with the relative controls under non-diabetic or diabetic conditions. After diabetes induction, A-FABP knockout mice exhibited a preserved cardiac function compared with that in wild-type mice. Endothelial cells, but not cardiomyocytes, were identified as the most likely source of cardiac A-FABP. Cardiac and circulating A-FABP levels were significantly increased in mice with diabetes or MI/R. Diabetes-induced superoxide anion production was significantly elevated in wild-type mice, but diminished in A-FABP knockout mice, and this elevation contributed to the exaggeration of MI/R-induced cardiac injury. Phosphorylation of endothelial nitric oxide synthase (eNOS) and production of nitric oxide (NO) were enhanced in both diabetic and non-diabetic A-FABP knockout mice after MI/R injury, but diminished in wild-type mice. The beneficial effects of A-FABP deficiency on MI/R injury were abolished by the NOS inhibitor N(G)-nitro-L-arginine methyl ester. Thus, A-FABP deficiency protects mice against MI/R-induced and/or diabetes-induced cardiac injury at least partially through activation of the eNOS/NO pathway and reduction in superoxide anion production.

show abstract

Serum Levels of Adipocyte Fatty Acid–Binding Protein are Independently Associated with Left Ventricular Mass and Myocardial Performance Index in Obstructive Sleep Apnea Syndrome

Cited by 25 publications

References 43 publications

Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese women

Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese women

Metabolic functions of FABPs—mechanisms and therapeutic implications

Deficiency of adipocyte fatty-acid-binding protein alleviates myocardial ischaemia/reperfusion injury and diabetes-induced cardiac dysfunction

Contact Info

Product

Resources

About